Jean Holloway Sells 3,079 Shares of Artivion (NYSE:AORT) Stock

Artivion, Inc. (NYSE:AORT) SVP Jean Holloway sold 3,079 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $37.59, for a total transaction of $115,739.61. Following the sale, the senior vice president directly owned 153,871 shares of the company’s stock, valued at approximately $5,784,010.89. The trade was a 1.96% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Artivion Stock Performance

NYSE:AORT opened at $38.14 on Friday. The stock has a market capitalization of $1.83 billion, a P/E ratio of 190.71 and a beta of 1.59. Artivion, Inc. has a 1 year low of $21.97 and a 1 year high of $48.25. The firm has a 50 day moving average of $42.09 and a 200-day moving average of $43.05. The company has a current ratio of 3.53, a quick ratio of 2.62 and a debt-to-equity ratio of 0.49.

Artivion (NYSE:AORT) last released its quarterly earnings results on Thursday, February 12th. The company reported $0.17 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.03. The firm had revenue of $118.30 million during the quarter, compared to analysts’ expectations of $116.42 million. Artivion had a return on equity of 7.43% and a net margin of 2.21%.Artivion’s quarterly revenue was up 19.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Artivion, Inc. will post 0.37 EPS for the current fiscal year.

Hedge Funds Weigh In On Artivion

Hedge funds and other institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in Artivion by 4.7% during the 4th quarter. Vanguard Group Inc. now owns 3,170,089 shares of the company’s stock worth $144,588,000 after acquiring an additional 141,030 shares during the period. Morgan Stanley boosted its position in shares of Artivion by 0.8% in the 4th quarter. Morgan Stanley now owns 2,256,742 shares of the company’s stock worth $102,930,000 after purchasing an additional 18,248 shares during the last quarter. State Street Corp grew its stake in shares of Artivion by 2.9% during the fourth quarter. State Street Corp now owns 1,584,920 shares of the company’s stock worth $72,288,000 after purchasing an additional 44,641 shares during the period. Fred Alger Management LLC grew its stake in shares of Artivion by 4.2% during the fourth quarter. Fred Alger Management LLC now owns 1,372,572 shares of the company’s stock worth $62,603,000 after purchasing an additional 55,322 shares during the period. Finally, Invesco Ltd. increased its holdings in Artivion by 211.9% in the fourth quarter. Invesco Ltd. now owns 1,101,239 shares of the company’s stock valued at $50,228,000 after purchasing an additional 748,119 shares during the last quarter. 86.37% of the stock is owned by institutional investors.

Key Artivion News

Here are the key news stories impacting Artivion this week:

• Positive Sentiment: Q4 results topped expectations — revenue grew ~19% year‑over‑year and EPS beat consensus, supporting revenue momentum and margin recovery; this helps justify the current rally. Earnings & Company Page
• Positive Sentiment: Short interest fell ~15.4% in February to ~1.39M shares (~3.2% of float); lower short exposure reduces one source of downside selling and can make up‑moves easier to sustain. Short Interest/Insider Page
• Positive Sentiment: Institutional investors have increased or initiated positions in recent quarters (multiple funds cited), indicating professional conviction that could support longer‑term demand. Institutional Holdings
• Neutral Sentiment: Analyst coverage is mixed — consensus is a “Moderate Buy” with an average target near $49, but some shops have trimmed targets or moved to Hold, reflecting divergent views on near‑term upside. Analyst Notes
• Negative Sentiment: Large, broad insider selling across Feb. 23–24 (CEO James P. Mackin, EVP Lance Berry, SVPs and CAO made sizable open‑market disposals). While filings suggest open‑market liquidity/scheduled sales rather than insider panic, the scale and breadth can create short‑term selling pressure and investor unease. SEC filings: CEO Form 4 and related officer filings. CEO Form 4 EVP Form 4

Wall Street Analyst Weigh In

A number of brokerages have commented on AORT. Oppenheimer reissued an “outperform” rating and set a $50.00 price objective on shares of Artivion in a report on Friday, November 7th. Needham & Company LLC reissued a “buy” rating and issued a $58.00 price target on shares of Artivion in a report on Monday, February 2nd. Wall Street Zen cut shares of Artivion from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Citizens Jmp upped their price objective on Artivion from $47.00 to $53.00 and gave the stock a “market outperform” rating in a report on Friday, November 7th. Finally, Weiss Ratings raised Artivion from a “sell (d)” rating to a “hold (c-)” rating in a research note on Friday, February 20th. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $48.97.

About Artivion

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.